SLC2A1 and cancer: A nanomedicine-based combination therapy using GLUT1 inhibitor and chemotherapeutic agent, curcumin, deprived cancer cells of glucose and sensitized cancer cells to chemotherapy, induced apoptosis, improved anti-tumor effects, and alleviated side-effects in vitro and in vivo [34].